Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate Meghna A Singhania11 April 2019 10:50 AM ISTMumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
Emcure launches generic Eribulin at 40 percent lower price in India Farhat Nasim4 April 2019 9:30 AM ISTEmcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal Garima29 March 2019 9:15 AM ISTUnder the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development...
Shilpa Medicare gets USFDA nod for Gemcitabine to treat types of cancer Farhat Nasim27 Feb 2019 9:30 AM ISTThe company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection...
Desi AI based healthtech startup NIRAMAI raises Rs 42.6 Crore in Series A Funding Garima25 Feb 2019 4:04 PM ISTBengaluru: Artificial intelligence based health tech startup NIRAMAI Health Analytics, has announced that it has closed $6 mn in a Series A round of...
NPPA likely to cap retailer margins of 73 cancer and rare disease drugs: Report Meghna A Singhania21 Feb 2019 3:13 PM ISTHowever, the move is likely to stimulate retailers to spend more as trade margins on drugs that have somehow bypassed the list and the retailers may...
Glenmark gets tentative USFDA nod to breast cancer injection Fulvestrant Farhat Nasim8 Feb 2019 11:40 AM ISTFulvestrant injection is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex injection in the same strength, it added. The Faslodex...
Pfizer quarterly profit in line, touts pipeline of future products Medical Dialogues Bureau31 Jan 2019 9:05 AM ISTOn a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would...
Roche plea in HC on cancer drug not maintainable: Biocon, Mylan Ruby Khatun Khatun12 Jan 2018 10:27 AM ISTNew Delhi: Generic drug makers Biocon and Mylan told the Delhi High Court that Swiss pharma major Roche's civil suit, challenging DCGI approvals...
Panacea Biotec gets USFDA nod to file for generic cancer drug Ruby Khatun Khatun2 Dec 2017 10:00 AM ISTNew Delhi: Panacea Biotec said the US health regulator has accepted its filing for approval of generic version of cancer treatment injection...
EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 10:00 AM ISTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Roche sues Pfizer to bar biosimilar of cancer drug Herceptin Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTRoche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block...
